Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2010, Vol. 4 Issue (4) : 457-462     DOI: 10.1007/s11684-010-0240-1
Research articles |
Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis
Shang-Long LIU1,Zi-Fang SONG1,Qing-Gang HU1,Shao-Bo HU1,Jun LI1,Qi-Chang ZHENG1,Duo SHAN2,
1.Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; 2.National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China;
Download: PDF(175 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen (CA) 19-9 levels in the survival of patients with cholangiocarcinoma. Articles published up to June 1st, 2010 that evaluated preoperative CA19-9 levels and the prognosis of cholangiocarcinoma were collected for meta-analysis. The required information for calculating individual relative risk (RR) was extracted from the studies, and a combined overall RR was estimated. Nine eligible studies were included. One study dealt with extra-hepatic cholangiocarcinoma, while the other eight studies analyzed intra-hepatic cholangiocarcinoma. The mean methodological quality score was 74.1%, ranging from 65.5% to 82.5%. The overall RR for the nine studies was 1.28 (95% confidence interval= 1.10–1.46), and the Z-score for overall effect was 13.83 (P<0.001). The association between serum CA19-9 level and lymph node involvement was also assessed. The combined RR was 1.471 (95% confidence interval= 0.411–5.264) and Z-score for overall effect was 0.59 (P = 0.553). CA19-9 levels were associated significantly with the prognosis of patients with cholangiocarcinoma. This meta-analysis shows that elevation of preoperative CA19-9 levels is correlated with a poor prognosis of patients with cholangiocarcinoma. However, larger scale and randomized studies are needed to draw a more substantive conclusion.
Keywords cholangiocarcinoma      prognostic factors      serum carbohydrate antigen 19-9      
Issue Date: 05 December 2010
URL:     OR
Blechacz B, Gores G J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology, 2008, 48(1): 308–321
PMID: 18536057
Welzel T M, McGlynn K A, Hsing A W, O'Brien T R, Pfeiffer R M. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors)on the incidence of intra- and extrahepatic cholangiocarcinoma inthe United States. J Natl Cancer Inst, 2006, 98(12): 873–875
PMID: 16788161
Forsmo H M, Horn A, Viste A, Hoem D, ?vreb? K. Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int, 2008, 7(4): 412–417
PMID: 18693178
Heimbach J K, Haddock M G, Alberts S R, Nyberg S L, Ishitani M B, Rosen C B, Gores G J. Transplantation for hilar cholangiocarcinoma. Liver Transpl, 2004, 10(10 Suppl 2): S65–S68
PMID: 15382214
Heimbach J K, Gores G J, Haddock M G, Alberts S R, Nyberg S L, Ishitani M B, Rosen C B. Liver transplantationfor unresectable perihilar cholangiocarcinoma. Semin Liver Dis, 2004, 24(2): 201–207
PMID: 15192792
Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O, Kinoshita H. Clinicopathological factorspredicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg, 2001, 88(7): 969–974
PMID: 11442529
DeOliveira M L, Cunningham S C, Cameron J L, Kamangar F, Winter J M, Lillemoe K D, Choti M A, Yeo C J, Schulick R D. Cholangiocarcinoma: thirty-one-yearexperience with 564 patients at a single institution. Ann Surg, 2007, 245(5): 755–762
PMID: 17457168
Su C H, Tsay S H, Wu C C, Shyr Y M, King K L, Lee C H, Lui W Y, Liu T J, P'eng F K. Factors influencing postoperative morbidity, mortality, and survivalafter resection for hilar cholangiocarcinoma. Ann Surg, 1996, 223(4): 384–394
PMID: 8633917
Stroup D F, Berlin J A, Morton S C, Olkin I, Williamson G D, Rennie D, Moher D, Becker B J, Sipe T A, Thacker S B. Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis Of Observational Studies inEpidemiology (MOOSE) group. JAMA, 2000, 283(15): 2008–2012
PMID: 10789670
Yusuf S, Peto R, Lewis J A, Collins R, Sleight P. Beta blockade during andafter myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 1985, 27(5): 335–371
PMID: 2858114
Miwa S, Miyagawa S, Soeda J, Kawasaki S. Matrix metalloproteinase-7 expression and biologic aggressivenessof cholangiocellular carcinoma. Cancer, 2002, 94(2): 428–434
PMID: 11900228
Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinicalfeatures and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg, 2006, 13(6): 537–542
PMID: 17139428
Yi B, Zhang B H, Zhang Y J, Jiang X Q, Zhang B H, Yu W L, Chen Q B, Wu M C. Surgical procedure and prognosis of hilarcholangiocarcinoma. Hepatobiliary PancreatDis Int, 2004, 3(3): 453–457
PMID: 15313688
Huang J L, Biehl T R, Lee F T, Zimmer P W, Ryan J A Jr. Outcomes after resectionof cholangiocellular carcinoma. Am J Surg, 2004, 187(5): 612–617
PMID: 15135676
Fernández-Ruiz M, Guerra-Vales J M, Colina-Ruizdelgado F. Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. World J Gastroenterol, 2009, 15(42): 5279–5286
PMID: 19908335
Abdel Wahab M, Fathy O, Elghwalby N, Sultan A, Elebidy E, Abdalla T, Elshobary M, Mostafa M, Foad A, Kandeel T, Abdel Raouf A, Salah T, Abu Zeid M, Abu Elenein A, Gad Elhak N, ElFiky A, Ezzat F. Resectability and prognosticfactors after resection of hilar cholangiocarcinoma. Hepatogastroenterology, 2006, 53(67): 5–10
PMID: 16506367
Kim H J, Yun S S, Jung K H, Kwun W H, Choi J H. Intrahepatic cholangiocarcinomain Korea. J Hepatobiliary Pancreat Surg, 1999, 6(2): 142–148
PMID: 10398901
Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Miyazaki M. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathologicalfactors influencing survival. Br J Surg, 2002, 89(12): 1525–1531
PMID: 12445060
Miwa S, Miyagawa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, Kusama K, Soeda J, Ogawa S. Predictive factors for intrahepatic cholangiocarcinomarecurrence in the liver following surgery. J Gastroenterol, 2006, 41(9): 893–900
PMID: 17048054
Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, Nishiguchi S, Kubo S. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol, 2008, 15(2): 583–589
PMID: 17955299
Zhou L, He X D, Cui Q C, Zhou W X, Qu Q, Zhou R L, Rui J A, Yu J C. Expression of LAPTM4B-35: a novel markerof progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett, 2008, 264(2): 209–217
PMID: 18334282
Shen W F, Zhong W, Xu F, Kan T, Geng L, Xie F, Sui C J, Yang J M. Clinicopathological and prognostic analysis of 429 patientswith intrahepatic cholangiocarcinoma. World J Gastroenterol, 2009, 15(47): 5976–5982
PMID: 20014463
Jiang W, Zeng Z C, Tang Z Y, Fan J, Zhou J, Zeng M S, Zhang J Y, Chen Y X, Tan Y S. Benefit of radiotherapy for 90 patients with resected intrahepaticcholangiocarcinoma and concurrent lymph node metastases. J Cancer Res Clin Oncol, 2010, 136(9): 1323–1331
PMID: 20130909
Cho S Y, Park S J, Kim S H, Han S S, Kim Y K, Lee K W, Lee S A, Hong E K, Lee W J, Woo S M. Survival analysis of intrahepaticcholangiocarcinoma after resection. Ann Surg Oncol, 2010, 17(7): 1823–1830
PMID: 20165987
Saxena A, Chua T C, Sarkar A, Chu F, Morris D L. Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resectionof intrahepatic cholangiocarcinoma: a 19-year experience from an establishedAustralian hepatobiliary unit. J Gastrointest Surg, 2010, 14(7): 1128–1138
PMID: 20467830
Kannagi R. Carbohydrate antigen sialyl Lewis a—its pathophysiologicalsignificance and induction mechanism in cancer progression. Chang Gung Med J, 2007, 30(3): 189–209
PMID: 17760270
Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, Kannagi R. Contribution of carbohydrate antigens sialyl Lewis Aand sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res, 1993, 53(2): 354–361
PMID: 7678075
Briggs C D, Neal C P, Mann C D, Steward W P, Manson M M, Berry D P. Prognostic molecular markers in cholangiocarcinoma: asystematic review. Eur J Cancer, 2009, 45(1): 33–47
PMID: 18938071
Berghmans T, Paesmans M, Mascaux C, Martin B, Meert A P, Haller A, Lafitte J J, Sculier J P. Thyroid transcription factor1—a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol, 2006, 17(11): 1673–1676
PMID: 16980598
Schoenleber S J, Kurtz D M, Talwalkar J A, Roberts L R, Gores G J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma:systematic review and meta-analysis. Br J Cancer, 2009, 100(9): 1385–1392
PMID: 19401698
[1] Wen Xue,Yan Sheng,Xiangqin Weng,Yongmei Zhu,Yan Zhao,Pengpeng Xu,Xiaochun Fei,Xiaoyan Chen,Li Wang,Weili Zhao. Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies: a single-institution study of 225 cases[J]. Front. Med., 2015, 9(4): 468-477.
[2] Yunfeng Fu, Xinyu Wang, Zimin Pan, Xing Xie. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases[J]. Front Med, 2014, 8(1): 91-95.
[3] Dong KUANG, Guo-Ping WANG, . Hilar cholangiocarcinoma: Pathology and tumor biology[J]. Front. Med., 2010, 4(4): 371-377.
[4] ZHANG Zongming, ZHU Jianping, SU Yanming, GUO Jinxing, JIANG Nan, ZHANG Zichao, XING Hailin, LIU Kai, YUAN Haiming. Diagnosis and treatment for advanced hilar cholangiocarcinoma: experience of 24 cases[J]. Front. Med., 2008, 2(2): 134-138.
Full text